RICCIUTI, BIAGIO
 Distribuzione geografica
Continente #
NA - Nord America 644
EU - Europa 358
AS - Asia 247
AF - Africa 1
OC - Oceania 1
Totale 1.251
Nazione #
US - Stati Uniti d'America 633
IE - Irlanda 137
SG - Singapore 89
IT - Italia 82
CN - Cina 61
HK - Hong Kong 50
VN - Vietnam 33
FI - Finlandia 28
RO - Romania 27
DE - Germania 21
FR - Francia 17
RU - Federazione Russa 17
CA - Canada 10
KR - Corea 8
CH - Svizzera 6
UA - Ucraina 6
GB - Regno Unito 3
GR - Grecia 3
SE - Svezia 3
UZ - Uzbekistan 3
IN - India 2
AT - Austria 1
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
DK - Danimarca 1
HU - Ungheria 1
LT - Lituania 1
MA - Marocco 1
MX - Messico 1
NL - Olanda 1
PL - Polonia 1
RS - Serbia 1
Totale 1.251
Città #
Chandler 179
Dublin 137
Singapore 69
San Mateo 57
Hong Kong 50
Boardman 36
Dong Ket 33
Santa Clara 32
Altamura 31
Bucharest 27
Lawrence 27
Medford 27
Princeton 27
Beijing 24
Wilmington 19
Helsinki 18
Perugia 18
Des Moines 12
Ottawa 10
Munich 9
San Paolo di Civitate 9
Ann Arbor 8
Seoul 8
Andover 7
Saint Petersburg 7
Norwalk 5
Redwood City 5
Arezzo 4
Los Angeles 4
Nanjing 4
New York 4
Redmond 3
Rome 3
Faenza 2
Paris 2
Simi Valley 2
Terni 2
Ashburn 1
Azcapotzalco 1
Baku 1
Brussels 1
Canberra 1
Chicago 1
Esslingen am Neckar 1
Falls Church 1
Frankfurt am Main 1
Guttingen 1
Houston 1
Kunming 1
Lappeenranta 1
Lausanne 1
Mozzo 1
Mumbai 1
Nagold 1
Nanchang 1
Sterling 1
Szeged 1
Tianjin 1
Vilnius 1
Xian 1
Zurich 1
Totale 945
Nome #
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 73
Non-coding RNAs in lung cancer 64
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 61
Antibody–drug conjugates for lung cancer in the era of personalized oncology 60
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence 59
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 56
Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications 55
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 54
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 54
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 52
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 51
Osimertinib 49
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 47
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 46
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 46
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 45
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 45
High density lipoprotein cholesterol and cancer: Marker or causative? 45
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 45
Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking 44
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 43
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 41
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 40
High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art 40
Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy 37
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 33
Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy 27
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 25
Totale 1.337
Categoria #
all - tutte 6.783
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.783


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202049 0 0 0 0 0 3 2 12 7 16 9 0
2020/2021100 2 0 2 1 50 6 0 5 0 0 1 33
2021/2022201 1 38 1 3 3 3 3 55 4 22 28 40
2022/2023530 28 104 12 39 47 56 0 29 189 0 22 4
2023/2024199 11 26 19 4 2 1 38 1 15 6 43 33
2024/2025154 9 30 36 16 44 19 0 0 0 0 0 0
Totale 1.337